Article Text

Download PDFPDF
Expression of Survivin, CD117, and C-erbB-2 in Neuroendocrine Carcinoma of the Uterine Cervix
  1. Kornkanok Sukpan, MD*,
  2. Jongkolnee Settakorn, MD*,
  3. Surapan Khunamornpong, MD*,
  4. Chalong Cheewakriangkrai, MD,
  5. Jatupol Srisomboon, MD and
  6. Sumalee Siriaunkgul, MD*
  1. *Departments of Pathology, and
  2. Departments of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  1. Address correspondence to Surapan Khunamornpong, MD, Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. E-mail: skhunamo{at}med.cmu.ac.th.

Abstract

Objective: To evaluate the expression and prognostic significance of survivin, CD117, and C-erbB-2 in neuroendocrine carcinoma of the uterine cervix.

Materials and Methods: Immunohistochemical stains of survivin, CD117, and C-erbB-2 were evaluated in 100 cases of cervical neuroendocrine carcinoma. The findings were correlated with clinicopathologic variables and disease-free survival.

Results: Expressions of survivin, CD117, and C-erbB-2 were detected in 27.0%, 12.0%, and 2.0% of the cases, respectively. Survivin-positive patients had a significantly younger mean age than the survivin-negative group (P = 0.033). In early-stage cases, tumor recurrence was significantly associated with lymph node metastasis (P = 0.005), depth of invasion (P = 0.028), and the presence of lymphovascular space invasion (P = 0.031) but not with the expression of survivin or CD117. Subgroup analysis in early-stage cases without lymph node metastasis (n = 32) showed that only survivin expression had a significant association with decreased disease-free survival (P = 0.041).

Conclusions: Survivin expression may be a prognostic indicator for survival in early-stage neuroendocrine carcinoma of the uterine cervix without lymph node metastasis. Adjuvant survivin-targeted therapy may have potential benefit in patients with this tumor.

  • Uterine cervix
  • Neuroendocrine carcinoma
  • Small cell carcinoma
  • Survivin
  • CD117
  • C-erbB-2 (HER-2/neu)

Statistics from Altmetric.com

Footnotes

  • This study was supported by The Thailand Research Fund and The National Research University Project under Thailand's Office of the Higher Education Commission.

  • The authors declare that there is no conflict of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.